

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <b>BURCAR ALISON D</b>  (Last) (First) (Middle) <b>951 CALLE AMANECER</b>  (Street) <b>SAN CLEMENTE CA 92673</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>ICU MEDICAL INC/DE [ ICU ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>Vice President and Gen'l Mgr.</b>
	3. Date of Earliest Transaction (Month/Day/Year) <b>06/18/2018</b>	
		6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/18/2018		X		17,108	A	\$58.79	21,311	D	
Common Stock <sup>(1)</sup>	06/18/2018		S		1,700	D	\$302.93 <sup>(2)</sup>	19,611	D	
Common Stock <sup>(1)</sup>	06/18/2018		S		1,800	D	\$304.16 <sup>(3)</sup>	17,811	D	
Common Stock <sup>(1)</sup>	06/18/2018		S		412	D	\$304.73 <sup>(4)</sup>	17,399	D	
Common Stock <sup>(1)</sup>	06/18/2018		S		100	D	\$305.9 <sup>(5)</sup>	17,299	D	
Common Stock	06/18/2018		S <sup>(6)</sup>		191	D	\$305.9 <sup>(5)</sup>	17,108	D	
Common Stock	06/18/2018		S		7,199	D	\$301.56 <sup>(7)</sup>	9,909	D	
Common Stock	06/18/2018		S		5,735	D	\$302.75 <sup>(8)</sup>	4,174	D	
Common Stock	06/18/2018		S		1,977	D	\$303.4 <sup>(9)</sup>	2,197	D	
Common Stock	06/18/2018		S		2,197	D	\$304.65 <sup>(10)</sup>	0	D	
Common Stock	06/19/2018		X		34,747	A	\$58.79	34,747	D	
Common Stock	06/19/2018		S		2,500	D	\$300.2 <sup>(11)</sup>	32,247	D	
Common Stock	06/19/2018		S		26,973	D	\$301.84 <sup>(12)</sup>	5,274	D	
Common Stock	06/19/2018		S		5,274	D	\$302.27 <sup>(13)</sup>	0	D	
Common Stock	06/20/2018		X		21,169	A	\$58.79	21,169	D	
Common Stock	06/20/2018		S		5,294	D	\$300.73 <sup>(14)</sup>	15,875	D	
Common Stock	06/20/2018		S		13,750	D	\$301.66 <sup>(15)</sup>	2,125	D	
Common Stock	06/20/2018		S		2,125	D	\$302.5 <sup>(5)</sup>	0	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$58.79	06/18/2018		X			17,108	(16)	02/24/2024	Common Stock	17,108	\$0.0 <sup>(17)</sup>	57,892	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$58.79	06/19/2018		X			34,747	(16)	02/24/2024	Common Stock	34,747	\$0.0 <sup>(17)</sup>	23,145	D	
Non-Qualified Stock Option (right to buy)	\$58.79	06/20/2018		X			21,169	(16)	02/24/2024	Common Stock	21,169	\$0.0 <sup>(17)</sup>	1,976	D	

**Explanation of Responses:**

- These securities are Restricted Stock Units.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$302.50 to \$303.50, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$303.55 to \$304.50, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$304.60 to \$304.85, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- All shares sold were sold at the exact price disclosed.
- Shares were previously acquired through the Registrant's Employee Stock Purchase Plan.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$301.00 to \$302.00, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$302.05 to \$303.05, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$303.10 to \$304.10, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$304.15 to \$305.10, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$300.00 to \$300.55, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$301.10 to \$302.10, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$302.13 to \$302.40, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$300.20 to \$301.20, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from \$301.30 to \$302.05, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- Options exercisable in four equal annual cumulative installments commencing one year after the grant date.
- Transaction is the exercise of a derivative security; see Column 2.

**Remarks:**

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2018.

By: Alejandro Parras, Attorney- 06/20/2018  
In-Fact For: Alison Burcar

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**